 "Image courtesy: Fresenius Kabi")
Akorn Inc, the US-based specialty generic pharmaceutical company, has confirmed that it is currently in discussions with Fresenius Kabi, a subsidiary of Fresenius SE & Co KGaA, concerning a potential acquisition of Akorn.
Entry into a formal agreement with respect to a transaction remains subject to, among other things, approval by the executive board and supervisory board of Fresenius Management SE and the board of directors of Akorn.
There can be no assurance any transaction will result from these discussions, or as to the terms of any such transaction. Neither Fresenius nor Akorn intend to make any additional comments regarding these negotiations
